| ［1］ |
George C, Deroide F, Rustin M. Pyoderma gangrenosum ⁃a guide to diagnosis and management［J］. Clin Med （Lond）, 2019,19（3）:224⁃228. doi: 10.7861/clinmedicine.19⁃3⁃224.
|
| ［2］ |
Maverakis E, Le ST, Callen J, et al. New validated diagnostic criteria for pyoderma gangrenosum［J］. J Am Acad Dermatol, 2019,80（4）:e87⁃e88. doi: 10.1016/j.jaad.2018.08.068.
|
| ［3］ |
Townsend T, Probert C. Editorial: peristomal pyoderma gangrenosum⁃a challenge for patients, healthcare professionals and research［J］. Aliment Pharmacol Ther, 2020,52（2）:404⁃405. doi: 10.1111/apt.15822.
|
| ［4］ |
Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum［J］. Nat Rev Dis Primers, 2020,6（1）:81. doi: 10.1038/s41572⁃020⁃0213⁃x.
|
| ［5］ |
Plumptre I, Knabel D, Tomecki K. Pyoderma gangrenosum: a review for the gastroenterologist［J］. Inflamm Bowel Dis, 2018,24（12）:2510⁃2517. doi: 10.1093/ibd/izy174.
|
| ［6］ |
Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine syndromes［J］. N Engl J Med, 2018,378（12）:1132⁃1141. doi: 10.1056/NEJMra1713301.
|
| ［7］ |
Chandrakasan S, Venkateswaran S, Kugathasan S. Nonclassic inflammatory bowel disease in young infants: immune dysregulation, polyendocrinopathy, enteropathy, X⁃linked syndrome, and other disorders［J］. Pediatr Clin North Am, 2017,64（1）:139⁃160. doi: 10.1016/j.pcl.2016.08.010.
|
| ［8］ |
Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment［J］. Expert Rev Clin Immunol, 2018,14（3）:225⁃233. doi: 10.1080/1744666X.2018.1438269.
|
| ［9］ |
Goldust M, Hagstrom EL, Rathod D, et al. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum［J］. Expert Rev Clin Pharmacol, 2020,13（2）:157⁃161. doi: 10.1080/17512433.2020.1709825.
|
